Full-Time

Full-Stack Software Engineer

Posted on 3/12/2025

Twist Bioscience

Twist Bioscience

1,001-5,000 employees

Produces synthetic DNA for biotechnology applications

Compensation Overview

$130k - $149.2k/yr

+ Bonus + Equity

Mid

No H1B Sponsorship

San Bruno, CA, USA

Hybrid role; specific in-office days not mentioned.

Category
Full-Stack Engineering
Software Engineering
Required Skills
Rust
Python
JavaScript
React.js
NoSQL
SQL
TypeScript
C#
Requirements
  • BS OR MS in Computer Science / Engineering and 3 + years industry experience or equivalent work experience
  • Proficient in modern Javascript on the front end and server-side (React, Node) experience
  • Python, Typescript, C# or Rust as back-end languages and ability to work with more than one programming language
  • SQL & NoSQL database modeling and optimization.

Twist Bioscience specializes in the synthesis of synthetic DNA, which is essential for various applications in biotechnology, pharmaceuticals, and research. The company produces high-quality DNA sequences that clients, including academic institutions and pharmaceutical companies, use for developing new drugs, diagnosing diseases, and conducting genetic research. Twist Bioscience differentiates itself by offering competitive pricing and a proprietary platform that allows for quick and accurate DNA production. This platform uses an algorithm to provide instant feedback on the synthesizability of DNA sequences. Their product range includes genes, oligo pools, variant libraries, and tools for SARS-CoV-2, along with DNA data storage and next-generation sequencing services. The company's goal is to be a leading supplier in the synthetic biology market, providing thousands of genes rapidly and supporting complex research projects.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for synthetic DNA in personalized medicine boosts Twist's market potential.
  • Collaboration with Absci leverages AI to accelerate antibody discovery and drug development.
  • Synthetic biology market projected to grow at 28.8% CAGR, benefiting Twist's growth.

What critics are saying

  • Increased competition from Ginkgo Bioworks may impact Twist's market share.
  • Dependency on AI technologies could pose integration and operational challenges.
  • New CIO appointment may lead to transitional challenges in IT strategy and operations.

What makes Twist Bioscience unique

  • Twist Bioscience uses a unique silicon-based DNA synthesis platform for precision and scale.
  • They offer high-quality DNA sequences at competitive prices, attracting diverse clients.
  • Their proprietary platform provides instant feedback on DNA sequence synthesis feasibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
TipRanks
Nov 26th, 2024
Twist Bioscience named a Best Idea for 2025 at TD Cowen

Twist Bioscience named a Best Idea for 2025 at TD Cowen.

SynBioBeta
Oct 31st, 2024
Absci and Twist Bioscience Team Up to Redefine Antibody Discovery with AI

Absci, a pioneer in generative AI-driven drug discovery, and Twist Bioscience, a leader in high-quality synthetic DNA production through its silicon platform, have announced an innovative collaboration to create a novel therapeutic antibody using generative AI.

Investing.com
Oct 25th, 2024
Twist Bioscience president sells $97,428 in stock

In other recent news, Twist Bioscience has secured a $15 million capital boost from a new financial agreement with XOMA Royalty Corporation.

Bakersfield.com
Oct 22nd, 2024
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.

Stock Titan
Oct 15th, 2024
Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer.

INACTIVE